Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

O. Rascol, N. Fabre, O. Blin, J. Poulik, U. Sabatini, J. M. Senard, M. Ane, J. L. Montastruc, A. Rascol

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.

Original languageEnglish
Pages (from-to)437-440
Number of pages4
JournalMovement Disorders
Volume9
Issue number4
DOIs
Publication statusPublished - 1994

Fingerprint

Opiate Alkaloids
Naltrexone
Parkinson Disease
Placebos
Bromocriptine
Dyskinesias
Levodopa
Cross-Over Studies
Opioid Analgesics
Therapeutics

Keywords

  • Motor symptoms
  • Naltrexone
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Rascol, O., Fabre, N., Blin, O., Poulik, J., Sabatini, U., Senard, J. M., ... Rascol, A. (1994). Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Movement Disorders, 9(4), 437-440. https://doi.org/10.1002/mds.870090410

Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. / Rascol, O.; Fabre, N.; Blin, O.; Poulik, J.; Sabatini, U.; Senard, J. M.; Ane, M.; Montastruc, J. L.; Rascol, A.

In: Movement Disorders, Vol. 9, No. 4, 1994, p. 437-440.

Research output: Contribution to journalArticle

Rascol, O, Fabre, N, Blin, O, Poulik, J, Sabatini, U, Senard, JM, Ane, M, Montastruc, JL & Rascol, A 1994, 'Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease', Movement Disorders, vol. 9, no. 4, pp. 437-440. https://doi.org/10.1002/mds.870090410
Rascol, O. ; Fabre, N. ; Blin, O. ; Poulik, J. ; Sabatini, U. ; Senard, J. M. ; Ane, M. ; Montastruc, J. L. ; Rascol, A. / Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. In: Movement Disorders. 1994 ; Vol. 9, No. 4. pp. 437-440.
@article{9e4dd5b85b62476f8b13f0a4631a6e95,
title = "Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease",
abstract = "One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.",
keywords = "Motor symptoms, Naltrexone, Parkinson's disease",
author = "O. Rascol and N. Fabre and O. Blin and J. Poulik and U. Sabatini and Senard, {J. M.} and M. Ane and Montastruc, {J. L.} and A. Rascol",
year = "1994",
doi = "10.1002/mds.870090410",
language = "English",
volume = "9",
pages = "437--440",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

AU - Rascol, O.

AU - Fabre, N.

AU - Blin, O.

AU - Poulik, J.

AU - Sabatini, U.

AU - Senard, J. M.

AU - Ane, M.

AU - Montastruc, J. L.

AU - Rascol, A.

PY - 1994

Y1 - 1994

N2 - One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.

AB - One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.

KW - Motor symptoms

KW - Naltrexone

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0027958852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027958852&partnerID=8YFLogxK

U2 - 10.1002/mds.870090410

DO - 10.1002/mds.870090410

M3 - Article

C2 - 7969211

AN - SCOPUS:0027958852

VL - 9

SP - 437

EP - 440

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 4

ER -